RAPT Therapeutics, Inc.
RAPT
$0.9067
-$0.0144-1.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.84% | 11.16% | 22.01% | 29.46% | 28.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.11% | -2.89% | 21.64% | 31.35% | 45.51% |
| Operating Income | -7.11% | 2.89% | -21.64% | -32.55% | -48.10% |
| Income Before Tax | -11.19% | 1.27% | -21.97% | -27.43% | -39.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.19% | 1.27% | -21.97% | -27.43% | -39.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.19% | 1.27% | -21.97% | -27.43% | -39.31% |
| EBIT | -7.11% | 2.89% | -21.64% | -32.55% | -48.10% |
| EBITDA | -7.19% | 3.00% | -21.69% | -32.77% | -48.49% |
| EPS Basic | -2.29% | 3.64% | -15.81% | -15.74% | -18.00% |
| Normalized Basic EPS | -1.19% | 3.53% | -15.54% | -15.47% | -20.38% |
| EPS Diluted | -2.29% | 3.64% | -15.81% | -15.74% | -18.00% |
| Normalized Diluted EPS | -1.19% | 3.53% | -15.54% | -15.47% | -20.38% |
| Average Basic Shares Outstanding | 6.35% | 2.74% | 5.65% | 10.74% | 17.88% |
| Average Diluted Shares Outstanding | 6.35% | 2.74% | 5.65% | 10.74% | 17.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |